Skip to content
2000
Volume 21, Issue 1
  • ISSN: 1573-4056
  • E-ISSN: 1875-6603
file format pdf download PDF
file format text download EPUB
side by side viewer icon HTML

Abstract

Introduction:

In nuclear medicine, Prostate-specific Membrane Antigen (PSMA) is a potential target for theranostics. Offering superior diagnostic accuracy to conventional imaging in prostate cancer (PCa), Gallium-68 labeled PSMA (68Ga-PSMA) positron emission tomography/computed tomography (PET/CT) is considered the new standard of care in PCa management. Tumor cells identified as PSMA-avid on PET/CT imaging can be targeted and eliminated with PSMA-labeled Lutetium-177 (177Lu-PSMA) therapy.

Case Presentation:

A sixty-eight years old patient who had metastatic castration-resistant PCa was reported in this study. Prior to receiving 177Lu-PSMA therapy, the patient’s PSA level was 358 ng/ml, and experienced extensive bone discomfort. Following ten cycles of 177Lu-PSMA therapy, exceptional results were observed.

Conclusion:

177Lu-PSMA therapy is likely to result in significantly better outcomes if first- or second-line treatments preserve the patient's bone marrow reserve or if the therapy is administered at earlier stages of the disease.

© 2025 The Author(s). Published by Bentham Science Publishers.
This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode
Loading

Article metrics loading...

/content/journals/cmir/10.2174/0115734056362468250709045212
2025-07-18
2025-09-19

  • From This Site

    /content/journals/cmir/10.2174/0115734056362468250709045212
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/cmir/21/1/CMIR-21-E15734056362468.html?itemId=/content/journals/cmir/10.2174/0115734056362468250709045212&mimeType=html&fmt=ahah

References

  1. RawlaP. Epidemiology of Prostate Cancer.World J. Oncol.2019102638910.14740/wjon119131068988
     [Google Scholar]
  2. KirbyM. HirstC. CrawfordE.D. Characterising the castration-resistant prostate cancer population: a systematic review.Int. J. Clin. Pract.201165111180119210.1111/j.1742‑1241.2011.02799.x21995694
     [Google Scholar]
  3. SeidenfeldJ. SamsonD.J. HasselbladV. AronsonN. AlbertsenP.C. BennettC.L. WiltT.J. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis.Ann. Intern. Med.2000132756657710.7326/0003‑4819‑132‑7‑200004040‑0000910744594
     [Google Scholar]
  4. SamsonD.J. SeidenfeldJ. SchmittB. HasselbladV. AlbertsenP.C. BennettC.L. WiltT.J. AronsonN. Systematic review and meta‐analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma.Cancer200295236137610.1002/cncr.1064712124837
     [Google Scholar]
  5. RahbarK. AhmadzadehfarH. KratochwilC. HaberkornU. SchäfersM. EsslerM. BaumR.P. KulkarniH.R. SchmidtM. DrzezgaA. BartensteinP. PfestroffA. LusterM. LützenU. MarxM. PrasadV. BrennerW. HeinzelA. MottaghyF.M. RufJ. MeyerP.T. HeuschkelM. EveslageM. BögemannM. FendlerW.P. KrauseB.J. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients.J. Nucl. Med.2017581859010.2967/jnumed.116.18319427765862
     [Google Scholar]
  6. von EybenF.E. RovielloG. KiljunenT. UprimnyC. VirgoliniI. KairemoK. JoensuuT. Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review.Eur. J. Nucl. Med. Mol. Imaging201845349650810.1007/s00259‑017‑3895‑x29247284
     [Google Scholar]
  7. SartorO. de BonoJ. ChiK.N. FizaziK. HerrmannK. RahbarK. TagawaS.T. NordquistL.T. VaishampayanN. El-HaddadG. ParkC.H. BeerT.M. ArmourA. Pérez-ContrerasW.J. DeSilvioM. KpameganE. GerickeG. MessmannR.A. MorrisM.J. KrauseB.J. VISION Investigators Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer.N. Engl. J. Med.2021385121091110310.1056/NEJMoa210732234161051
     [Google Scholar]
  8. KratochwilC. FendlerW.P. EiberM. HofmanM.S. EmmettL. CalaisJ. OsborneJ.R. IravaniA. KooP. LindenbergL. BaumR.P. BozkurtM.F. Delgado BoltonR.C. EzziddinS. ForrerF. HicksR.J. HopeT.A. KabasakalL. KonijnenbergM. KopkaK. LassmannM. MottaghyF.M. OyenW.J.G. RahbarK. SchoderH. VirgoliniI. BodeiL. FantiS. HaberkornU. HermannK. Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT).Eur. J. Nucl. Med. Mol. Imaging20235092830284510.1007/s00259‑023‑06255‑837246997
     [Google Scholar]
  9. GafitaA. CalaisJ. GroganT.R. HadaschikB. WangH. WeberM. SandhuS. KratochwilC. EsfandiariR. TauberR. ZeldinA. RathkeH. ArmstrongW.R. RobertsonA. ThinP. D’AlessandriaC. RettigM.B. DelpassandE.S. HaberkornU. ElashoffD. HerrmannK. CzerninJ. HofmanM.S. FendlerW.P. EiberM. Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study.Lancet Oncol.20212281115112510.1016/S1470‑2045(21)00274‑634246328
     [Google Scholar]
  10. SunM. NiazM.O. NelsonA. SkafidaM. NiazM.J. Review of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer.Cureus2020126e892110.7759/cureus.892132760622
     [Google Scholar]
  11. SeitzerK.E. SeifertR. KesselK. RollW. SchlackK. BoegemannM. RahbarK. Lutetium-177 labelled PSMA targeted therapy in advanced prostate cancer: Current status and future perspectives.Cancers20211315371510.3390/cancers1315371534359614
     [Google Scholar]
  12. AhmadzadehfarH. WegenS. YordanovaA. FimmersR. KürpigS. EppardE. WeiX. SchlenkhoffC. HauserS. EsslerM. Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617.Eur. J. Nucl. Med. Mol. Imaging20174491448145410.1007/s00259‑017‑3716‑228488028
     [Google Scholar]
  13. WrengerR. JüptnerM. MarxM. ZhaoY. ZuhayraM. CaliebeA. OsmonovD. LützenU. Pre- and intratherapeutic predictors of overall survival in patients with advanced metastasized castration-resistant prostate cancer receiving Lu-177-PSMA-617 radioligand therapy.BMC Urol.20222219610.1186/s12894‑022‑01050‑335788220
     [Google Scholar]
  14. SchuchardtC. ZhangJ. KulkarniH.R. ChenX. MüllerD. BaumR.P. Prostate-specific membrane antigen radioligand therapy using 177Lu- PSMA I&T and 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: Comparison of safety, biodistribution, and dosimetry.J. Nucl. Med.20226381199120710.2967/jnumed.121.26271334887335
     [Google Scholar]
  15. MichalskiK. RufJ. GoetzC. SeitzA.K. BuckA.K. LapaC. HartrampfP.E. Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy.Eur. J. Nucl. Med. Mol. Imaging20214862024203010.1007/s00259‑020‑05160‑833336265
     [Google Scholar]
/content/journals/cmir/10.2174/0115734056362468250709045212
Loading
A Case Report on the Dramatic Response of 177Lu-PSMA Therapy for Metastatic Prostate Cancer
Curr. Med. Imaging 21, E15734056362468 (2025); https://doi.org/10.2174/0115734056362468250709045212
/content/journals/cmir/10.2174/0115734056362468250709045212
/content/journals/cmir/10.2174/0115734056362468250709045212
Loading

Data & Media loading...


  • Article Type:     Case Report
Keyword(s): 177Lu-PSMA; Metastatic castration-resistant prostate cancer; Prostate cancer; Prostate-specific membrane antigen; Radioligand therapy; Theranostics

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test